首页 › 基金 › Royalty Pharma Sub-Manager, LLC › KLRA

Royalty Pharma Sub-Manager, LLC 对 KLRA 的持仓历史

KAILERA THERAPEUTICS INC · 医疗保健

Royalty Pharma Sub-Manager, LLC 在 Q3 2026 的 13F 申报中披露持有 KLRA(KAILERA THERAPEUTICS INC)2,455,357 股,市值约 US$28.0M,约占其申报组合的 14.29%,在其申报持仓中市值排名第 4 位。 Royalty Pharma Sub-Manager, LLC 最近 2 个申报季度中有 2 个季度披露了 KLRA 持仓,最早可追溯至 Q2 2026。

最新持仓 (Q3 2026)2.46M 股
申报持仓市值$28.04M
组合权重14.29%
首次申报Q2 2026
最近变动持有
更新于2026-11-14

最后更新: 2026-11-14 · 来源: SEC EDGAR Form 13F-HR

Royalty Pharma Sub-Manager, LLC 对 KLRA 的持仓演变

Royalty Pharma Sub-Manager, LLC 于 Q2 2026 首次披露 KLRA 持仓:2,455,357 股(约 US$54.1M)。 在 2 次申报中,Royalty Pharma Sub-Manager, LLC 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 2,455,357 股、市值约 US$28.0M。

逐季持仓明细

季度股数金额变化
Q2 2026 2.46M $54.09M 新进
Q3 2026 2.46M $28.04M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 KLRA 与 13F 数据

KLRA(KAILERA THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 131 只申报持有 KLRA,申报仓位最大的包括:BAIN CAPITAL INVESTORS LLC (US$578.4M), Bain Capital Life Sciences Investors, LLC (US$497.5M), RTW INVESTMENTS, LP (US$237.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 KLRA 的基金

查看 KLRA 的全部基金持有人 →

常见问题

How long has Royalty Pharma Sub-Manager, LLC held KLRA?

Royalty Pharma Sub-Manager, LLC has disclosed KLRA holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Royalty Pharma Sub-Manager, LLC's current position in KLRA?

As of Q3 2026, Royalty Pharma Sub-Manager, LLC holds 2.46M shares of KLRA (KAILERA THERAPEUTICS INC), valued at $28.04M, representing 14.29% of its reported portfolio and ranking #4.

Has Royalty Pharma Sub-Manager, LLC been buying or selling KLRA?

In the latest 13F filing (Q3 2026), Royalty Pharma Sub-Manager, LLC held unchanged its position in KLRA.

Which other funds hold KLRA?

Other major institutional holders of KLRA include BAIN CAPITAL INVESTORS LLC, Bain Capital Life Sciences Investors, LLC, RTW INVESTMENTS, LP, among 131 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.